Research Article
Chordin-Like 2: A Possible Therapeutic Target for Gastric Cancer by Affecting Cell Cycle and Proliferation
Table 1
Correlation of CHRDL2 with clinicopathological parameters in patients with gastric cancer.
| | Characteristics | Levels | Low expression of CHRDL2 | High expression of CHRDL2 | p |
| | n | | 187 | 188 | | | T stage, n (%) | T1 | 16 (4.4%) | 3 (0.8%) | 0.010 | | T2 | 43 (11.7%) | 37 (10.1%) | | T3 | 82 (22.3%) | 86 (23.4%) | | T4 | 43 (11.7%) | 57 (15.5%) |
| | N stage, n (%) | N0 | 63 (17.6%) | 48 (13.4%) | 0.276 | | N1 | 45 (12.6%) | 52 (14.6%) | | N2 | 37 (10.4%) | 38 (10.6%) | | N3 | 32 (9%) | 42 (11.8%) |
| | M stage, n (%) | M0 | 163 (45.9%) | 167 (47%) | 0.415 | | M1 | 15 (4.2%) | 10 (2.8%) |
| | Pathologic stage, n (%) | Stage I | 38 (10.8%) | 15 (4.3%) | 0.002 | | Stage II | 53 (15.1%) | 58 (16.5%) | | Stage III | 64 (18.2%) | 86 (24.4%) | | Stage IV | 22 (6.2%) | 16 (4.5%) |
| | Primary therapy outcome, n (%) | SD | 8 (2.5%) | 9 (2.8%) | 0.414 | | PD | 37 (11.7%) | 28 (8.8%) | | CR | 109 (34.4%) | 122 (38.5%) | | PR | 1 (0.3%) | 3 (0.9%) |
| | Gender, n (%) | Male | 118 (31.5%) | 123 (32.8%) | 0.718 | | Female | 69 (18.4%) | 65 (17.3%) | |
| | Race, n (%) | Asian | 43 (13.3%) | 31 (9.6%) | 0.014 | | White | 101 (31.3%) | 137 (42.4%) | | Black or African American | 8 (2.5%) | 3 (0.9%) |
| | Histological type, n (%) | Diffuse type | 26 (7%) | 37 (9.9%) | 0.010 | | Mucinous type | 5 (1.3%) | 14 (3.7%) | | Not otherwise specified | 105 (28.1%) | 102 (27.3%) | | Papillary type | 3 (0.8%) | 2 (0.5%) | | Signet ring type | 3 (0.8%) | 8 (2.1%) | | Tubular type | 45 (12%) | 24 (6.4%) |
| | Age, n (%) | ≤65 | 72 (19.4%) | 92 (24.8%) | 0.065 | | >65 | 112 (30.2%) | 95 (25.6%) |
| | Residual tumor, n (%) | R0 | 146 (44.4%) | 152 (46.2%) | 0.296 | | R1 | 8 (2.4%) | 7 (2.1%) | | R2 | 11 (3.3%) | 5 (1.5%) |
| | Histologic grade, n (%) | G1 | 5 (1.4%) | 5 (1.4%) | 0.017 | | G2 | 81 (22.1%) | 56 (15.3%) | | G3 | 96 (26.2%) | 123 (33.6%) |
| | Anatomic neoplasm subdivision, n (%) | Fundus/body | 62 (17.2%) | 68 (18.8%) | 0.014 | | Cardia/proximal | 23 (6.4%) | 25 (6.9%) | | Gastroesophageal junction | 29 (8%) | 12 (3.3%) | | Antrum/distal | 64 (17.7%) | 74 (20.5%) | | Other | 4 (1.1%) | 0 (0%) |
| | Reflux history, n (%) | No | 88 (41.1%) | 87 (40.7%) | 1.000 | | Yes | 20 (9.3%) | 19 (8.9%) |
| | Anti-reflux treatment, n (%) | No | 71 (39.7%) | 71 (39.7%) | 0.257 | | Yes | 14 (7.8%) | 23 (12.8%) |
| | H. pylori infection, n (%) | No | 88 (54%) | 57 (35%) | 0.050 | | Yes | 6 (3.7%) | 12 (7.4%) |
| | Barrett’s oesophagus, n (%) | No | 106 (51%) | 87 (41.8%) | 0.911 | | Yes | 9 (4.3%) | 6 (2.9%) |
| | Age, median (IQR) | | 68 (59, 74.25) | 66 (57, 72) | 0.075 |
|
|
